Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol

The Journal of Clinical Psychiatry
K C ColeyR A Branch

Abstract

Therapeutic ineffectiveness and noncompliance with antipsychotic agents are major contributors to rehospitalization in patients with psychotic disorders. It is unknown whether risperidone's favorable side effect profile compared with that of the conventional antipsychotics results in improved compliance and reduced hospitalizations in a naturalistic setting. The purpose of this study was to test the hypothesis that treatment with risperidone reduces readmission rates and associated costs when compared with treatment with perphenazine or haloperidol. Inpatients prescribed either risperidone, perphenazine, or haloperidol between January 1, 1995, and December 31, 1995, as a single oral antipsychotic at discharge were retrospectively identified. Data were collected for that index hospitalization and for a 1-year follow-up period. Primary outcome measures included re-admission rates, changes in antipsychotic therapy, anticholinergic drug use, and costs. There were 202 evaluable patients (81 treated with risperidone, 78 with perphenazine, and 43 with haloperidol). Baseline demographics were similar between groups except that more patients in the risperidone group had a primary diagnosis of psychotic disorder or had been hospitalized ...Continue Reading

Citations

Apr 20, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Claire AdvokatJoseph E Comaty
Apr 7, 2007·International Clinical Psychopharmacology·David TaylorRobert Kerwin
Nov 1, 2006·International Journal of Clinical Practice·F GianfrancescoK Rajagopalan
Nov 14, 2007·International Journal of Clinical Practice·M ObradovicM Kos
Feb 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Reinhold Kilian, Thomas Becker
May 29, 2008·Expert Review of Neurotherapeutics·David Suarez, Josep Maria Haro
Nov 21, 2007·European Psychiatry : the Journal of the Association of European Psychiatrists·Antonio CiudadInmaculada Gilaberte
Jan 9, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Linda M DaviesUNKNOWN CUTLASS Team
Oct 16, 2007·The Journal of Emergency Medicine·Kim C ColeyAmy L Seybert
Apr 1, 2006·Journal of Psychopharmacology·Peter Haddad, Serdar Murat Dursun
Jan 27, 2004·The Annals of Pharmacotherapy·Gordon G LiuXuemei Luo
Jul 21, 2006·Journal of Clinical Psychopharmacology·Frank GianfrancescoRuey-hua Wang
Feb 11, 2004·The Journal of Nervous and Mental Disease·David S SalkeverPatricia A Russo
May 16, 2008·Journal of Clinical Psychopharmacology·Susan Shur-Fen GauChurn-Shiouh Gau
Feb 13, 2003·Acta Psychiatrica Scandinavica·J M HaroUNKNOWN SOHO Study Group
May 21, 2003·Acta Psychiatrica Scandinavica. Supplementum·J M HaroUNKNOWN SOHO Study Group
May 7, 2004·Hospital Medicine·Marcelo Camprubi, Luiz Dratcu
Jul 4, 2006·CNS Spectrums·Herbert Y Meltzer, William V Bobo
Aug 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sylvia ParkStephen B Soumerai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here